Date: 2014-04-07
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California, USA.
Company: Basilea Pharmaceutica (Switzerland)
Product: BAL101553
Action
mechanism:
- microbutubule inhibitor. BAL101553 is an intravenous and oral microtubule-targeting agent. This highly water-soluble prodrug of the synthetic small molecule BAL27862 allows intravenous and oral administration without solubilizing excipients associated with adverse effects. BAL27862 arrests tumor cell proliferation and induces tumor cell death through a characteristic destabilizing effect on microtubules that is distinct from other anti-cancer agents also directed against the microtubule network. Anti-tumor activity has been demonstrated across a broad panel of solid tumor models, including those resistant against conventional microtubule-targeting drugs such as taxanes or Vinca alkaloids.
Disease: breast cancer
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On April 7, 2014, Basilea Pharmaceutica has reported that new data demonstrating the broad activity of Basilea's novel oncology drug candidate BAL101553 in pre-clinical models of human breast cancer, including models resistant to standard agents used for the treatment of breast cancer, were presented at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California, USA. The presented data was generated in cooperation between Basilea and the group of Prof. Sikic at Stanford University. BAL27862, the active moiety of the prodrug BAL101553, demonstrated anti-proliferative activity in several breast cancer cell lines, including multidrug-resistant lines that no longer respond to, or are inherently resistant to, paclitaxel and vincristine, two standard microtubule-targeting breast cancer therapies. Intravenous administration of BAL101553 in an animal model of chemotherapy-refractory human breast cancer led to a significantly reduced rate of tumor growth when compared to paclitaxel and vincristine. Antitumor activity was also observed in breast cancer models refractory to treatment with the therapeutic antibody trastuzumab. The combination of BAL101553 with trastuzumab strikingly exhibited enhanced antitumor activity versus the single agents in a patient-derived trastuzumab-refractory model. This was associated with a significant delay in tumor growth over an extended time period.
Is
general: Yes
